CN101454295B - 猪科动物或羊用抗口蹄疫病毒药剂 - Google Patents
猪科动物或羊用抗口蹄疫病毒药剂 Download PDFInfo
- Publication number
- CN101454295B CN101454295B CN200780019955XA CN200780019955A CN101454295B CN 101454295 B CN101454295 B CN 101454295B CN 200780019955X A CN200780019955X A CN 200780019955XA CN 200780019955 A CN200780019955 A CN 200780019955A CN 101454295 B CN101454295 B CN 101454295B
- Authority
- CN
- China
- Prior art keywords
- foot
- mouth disease
- sheep
- salt
- disease virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 46
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims abstract description 26
- 241001494479 Pecora Species 0.000 title claims abstract description 14
- 241000700605 Viruses Species 0.000 title abstract description 15
- 241000282887 Suidae Species 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960005206 pyrazinamide Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 abstract description 8
- 208000030194 mouth disease Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- -1 PHARMA GRADE Chemical compound 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000005723 virus inoculator Substances 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000405217 Viola <butterfly> Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010050256 Dysstasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000276489 Merlangius merlangus Species 0.000 description 1
- CMEWLCATCRTSGF-UHFFFAOYSA-N N,N-dimethyl-4-nitrosoaniline Chemical compound CN(C)C1=CC=C(N=O)C=C1 CMEWLCATCRTSGF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical group C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Abstract
本发明涉及含有3-氧代-3,4-二氢-2-吡嗪甲酰胺或其盐的猪科动物用抗口蹄疫病毒药剂。该药剂对猪科动物的口蹄疫的预防或治疗极为有效。并且,本发明还涉及含有3-氧代-3,4-二氢-2-吡嗪甲酰胺或其盐的羊用抗口蹄疫病毒药剂。该药剂对羊的口蹄疫的预防或治疗等也极为有效。
Description
技术领域
本发明涉及含有3-氧代-3,4-二氢-2-吡嗪甲酰胺(以下称T-1105)或其盐的猪科动物或羊(以下称“猪科动物等”)用抗口蹄疫病毒药剂、含有T-1105或其盐的猪科动物等用饲料以及猪科动物等的口蹄疫的预防和治疗方法等的处理方法。
背景技术
口蹄疫是对家畜中的牛、猪及羊等偶蹄类动物传染力很强的疾病之一,会引起家畜的发育障碍、运动障碍等,是使家畜商品价值骤降的家畜特异性感染病,但对人不具感染性。对于世界畜牧业来说,无论是在出口国还是进口国的立场上,口蹄疫都位居最应该警戒且最重要的家畜传染病。
口蹄疫是国际性传染病,目前仍在亚洲、非洲及南美洲等世界各地广为流行。日本也于2000年发生了口蹄疫。一旦口蹄疫发生,由于口蹄疫病毒的传染性极强,对于防止其传播会伴有巨大的困难。一旦口蹄疫发生,对畜牧业的打击将会极其巨大。因此,在包括口蹄疫预防及治疗等的处理上,全世界付出了极大的努力。
控制口蹄疫的对策有,严格的进口管制、卫生管理、检疫的实施以及罹患动物的屠宰,在大流行时,则在地区水平或发病周边区域实施作为预防手段的使用灭活疫苗的预防接种程序。然而,口蹄疫的早期发现很难,且会以非常快的速度传播,疫苗接种无法及时到位。而且病毒容易发生变异,仅以疫苗的接种无法完全防止感染。也就是说,目前并不存在针对偶蹄目动物中猪科动物等的优良的口蹄疫治疗方法。
国际公开第WO00/10569号小册子上记载到,T-1105具有优良的抗流感病毒作用(专利文献1)。然而,对于猪科动物等用的抗口蹄疫病毒药剂以及对猪科动物等的口蹄疫的预防或治疗方法等的处理方法,还未见具体地公开。
专利文献1:国际公开第WO00/10569号小册子
发明内容
发明要解决的课题
优良的猪科动物等用抗口蹄疫病毒药剂以及对猪科动物等的口蹄疫的预防或治疗方法等处理方法受到强烈的需求。
解决课题的方法
在此情况下,本发明人进行了深入研究,结果发现,含有T-1105或其盐的抗口蹄疫病毒药剂对猪科动物具有很强的口蹄疫治疗效果,在对猪科动物的口蹄疫的治疗等的处理方面有效,从而完成了本发明。
进而发现,含有T-1105或其盐的抗口蹄疫病毒药剂对羊(绵羊)具有很强的口蹄疫治疗效果,在对羊的口蹄疫的治疗等的处理方面有效,从而完成了本发明。
发明效果
含有T-1105或其盐的抗口蹄疫病毒药剂在对猪科动物等的口蹄疫的预防和治疗等的处理方面有效。
具体实施方式
以下对本发明进行详细说明。
在本说明书中,只要未特别指出,当T-1105或其盐存在溶剂化物和水合物时,也可以使用它们的溶剂化物和水合物。并且,也可以使用各种形状的结晶。
作为T-1105的盐来说,可举出通常已知的在羟基上形成的盐。作为在羟基上形成的盐,可举出:与钠和钾等碱金属形成的盐;与钙和镁等碱土金属形成的盐;铵盐;以及与三甲胺、三乙胺、三丁胺、吡 啶、N,N-二甲基苯胺、N-甲基哌啶,N-甲基吗啉、二乙胺、二环己胺、普鲁卡因、二苄胺、N-苄基-β-苯乙胺、1-二苯羟甲胺(ephenamine)、N,N′-二苄基乙二胺等含氮有机碱形成的盐。上述盐中,作为优选的盐,可举出药理学可接受的盐,进一步优选与钠之间的盐。
针对属于口蹄病毒属的口蹄疫病毒,本发明的含有T-1105或其盐的猪科动物等用的抗口蹄疫病毒药剂显示出优良的抗病毒作用。作为口蹄疫病毒,可举出血清型为A、O及C的欧洲型;血清型为Asia 1的亚洲型和血清型为SAT1、SAT2及SAT3的非洲型、以及它们的亚型。
特别是针对血清型为A、O和C、以及出现在亚洲的Asia1的病毒,本发明的含有T-1105或其盐的猪科动物等用的抗口蹄疫病毒药剂具有更为优良的效果。
本发明中所述的猪科动物是指脊椎动物门哺乳纲偶蹄目猪科动物,具体地,可举出家猪和野猪,特别优选猪。
T-1105或其盐可以经注射用蒸馏水或生理盐水等稀释之后作为注射剂对猪科动物等非口服给药,或者可以按照公知的制剂学制造方法,根据需要使用制剂学允许的稀释剂、赋形剂,制成片剂、大型丸剂、粉末、颗粒剂、细粒剂、胶囊、乳剂、液体制剂、混悬剂、预混剂、糖浆、糊剂或气雾剂等动物用制剂,口服或非口服给药。
对于T-1105或其盐、或者其动物用制剂,可以根据需要使其混合在饲料中使用,例如,可以添加到包括干草、稻草类、牧草类、青刈饲料作物类、根果菜类、野草类、树叶类及青贮饲料等粗饲料;以及谷类、油粕类和复合饲料等浓缩饲料等饲料中使用。并且,可以添加到饮用水等中使用。
作为优选的给药形式,可举出制成包括肌肉注射、皮下注射及腹腔内注射等的注射剂的给药形式以及将T-1105混合在饲料内而混食口服的给药形式。
对于本发明的猪科动物等用的抗口蹄疫病毒药剂以及猪科动物等用饲料,例如,可以将T-1105或其盐用固态或液态的载体通过稀释或包覆等方法进行稳定化,例如制成片剂、大型丸剂、粉末、颗粒剂、 细粒剂、胶囊、乳剂、液体制剂、混悬剂、预混剂、糖浆、糊剂或气雾剂等,或者使其分散于载体中之后或者直接添加至饲料或饮料中来制造。作为固体载体,可举出乳糖、蔗糖、淀粉、小麦粉、玉米粉、麸子、大豆油粕、脱脂米糠、菜籽油粕、豆腐粕、纤维素、酵母菌、鱼粉、花生榨渣、贝壳粉及碳酸钙等,作为液态载体,可举出水、生理盐水及生理学上无害的有机溶剂。并且,根据需要,也可以添加诸如乳化剂、分散剂、助悬剂、润湿剂、浓缩剂、胶凝剂及增溶剂等的辅助剂。本发明药剂也可以是预混合的形式。此外,也可以配合防腐剂、灭菌剂、驱虫剂、抗氧化剂、着色剂、芳香剂、抗菌剂、抗生素、酶制剂、乳酸菌制剂、退热剂、镇痛剂和消炎剂等。也可以配合其他动物药。而且,可以配合各种维生素类、矿物类及氨基酸类等。
本发明的猪科动物等用的抗口蹄疫病毒药剂是以口蹄疫的预防或/和治疗等处理为目的给药至猪科动物等家畜或动物的。尤其优选应用于猪。
对于给药剂量,可以根据对象动物的年龄、体重、症状和给药途径进行适当选择,举例来说,可以相对于动物的体重以1天1~2000mg/kg的剂量分1次至多次给药。也可以根据症状增加给药次数。另外,对给药期间无特别限制,但一般通过1~10天的给药就能获得足够的效果,且也可以间断性的给药。
实施例
下面,列举试验例对本发明进行说明,但本发明并不限定于此。本发明的T-1105或其盐可以通过购买市售品得到,或者通过公知方法或基于公知方法的方法以及将这些方法进行组合来制造。另外,试验例1~3是在独立行政法人、农业·食品产业技术综合研究机构、动物卫生研究所(东京都)实施的。
试验例1体外抗口蹄疫病毒作用
(1)测定T-1105对口蹄疫病毒(O/JPN/2000株)的效果。
将口蹄疫病毒(O/JPN/2000株)吸附(37℃,1小时)于猪源肾脏继代细胞,以达到约30~100个/盘。除去病毒液,用已调节为pH7.4 的MEM培养基进行清洗之后,覆盖将T-1105从20μg/mL经二次稀释的含有2%牛血清加1.5%甲基纤维素的MEM培养基。培养3天,并用含0.2%结晶紫的10%中性缓冲福尔马林将细胞固定后,进行染色,对空斑进行计数。与未添加药剂组的空斑数进行比较,求得50%空斑形成抑制率(IC50)。
结果为1.6μg/mL。
(2)测定T-1105对口蹄疫病毒(A、C及Asia 1)的效果。
A、C和Asia 1的病毒浓度分别为10 TCID50、10 TCID50和101.5TCID50,将病毒吸附于IBRS-2细胞(37℃,1小时)后,添加被从20μg/mL二次稀释了的T-1105,48小时之后用含0.2%结晶紫的10%中性缓冲福尔马林将细胞固定后,进行染色。在各个浓度上,如果4孔中1孔以上观察到对细胞病变效果的抑制,则该浓度判定为有效。
结果示于表1。
[表1]
T-1105显示了针对口蹄疫病毒的优良的效果。
试验例2(1) T-1105的药代动力学试验(猪、牛)
对猪(普通级,体重10kg,2头)以及牛(日本黑毛和牛,体重200kg,2头)进行了1% T-1105复合饲料的口服给药,给药剂量为100mg/kg。在给药后2小时和8小时,用经肝素润洗的注射筒从各动物的颈静脉采血1.5mL,然后迅速进行离心分离(4℃,2000rpm,10分钟),将250μL血浆分别注入到1.5mL微管内。以使用了空白血浆的标准曲线为基础,测定了T-1105的浓度。其中,为制作标准曲线,向200μL空白血浆中添加5倍浓度的T-1105溶液50μL,实施与血浆前处理操作相同的操作。分别向250μL血浆试样和250μL标准曲线用血浆试样中添加500μL甲醇 并搅拌,并将所得溶液进行离心分离(10000rpm,4℃,10分钟)。收集上清液,经除蛋白处理之后,进行减压干燥。用500μL的HPLC流动相溶解残渣,并进行离心分离(3000rpm,10℃,10分钟),收集上清液,作为测定样品。以下述HPLC条件进行测定。
分析柱:Develosil ODS-MG-5(4.6mm I.D.×250mm),野村化学株式会社制
保护柱:Develosil ODS-MG-5(4.0mm I.D.×10mm),野村化学株式会社制
柱温:40℃
HPLC流动相:甲醇/1mol/L磷酸盐缓冲液(pH7.0)/蒸馏水/TBA-Br(50:50:900:1.6,v/v/v/w)
流速:1.0mL/min
检测波长:350nm
进样量:100μL
自动进样器温度:预设温度10℃
分析时间:约18分钟
制作标准曲线,由峰面积求取血浆试样中各个个体的T-1105浓度,并计算其平均值。
试验例2(2)T-1105的药代动力学试验(羊)
对羊(考力代羊,体重63kg和67kg,2头)进行了1%T-1105复合饲料的口服给药,给药剂量为100mg/kg。在给药后的2小时及8小时,使用经肝素润洗的注射筒从各个个体的颈静脉采血1.5mL,然后迅速进行离心分离(4℃,2000rpm,10分钟),将250μL血浆分别注至1.5mL微管中。向血浆试样中添加500μL甲醇并搅拌,并进行离心分离(10000rpm,4℃,10分钟)。收集上清液,经除蛋白处理之后,进行减压干燥。用500μL的HPLC流动相溶解残渣,并进行离心分离(3000rpm,10℃,10分钟),收集上清液,作为测定样品。以与试验例2(1)相同的条件进行测定。
用标准液制作标准曲线,由峰面积求出血浆试样中各个个体的 T-1105浓度,并计算其平均值。
试验例2(1)和(2)的结果示于表2。
[表2]
T-1105在猪及羊体内维持了高血药浓度,显示了优良的药代动力学性能。
试验例3混食给药的有效性试验
使用猪全身感染模型评价了T-1105对口蹄疫的治疗效果。
对猪(普通级,体重10kg,给药组2头(猪编号1和2)、非给药组2头(猪编号3和4))将口蹄疫病毒106 TCID50接种于前肢足垫处,以诱发感染。
在接种病毒1小时前按200mg/kg的剂量进行T-1105的口服混食给药,在之后的6.5天期间,1天2次(400mg/kg/天)给药。在接种病毒后8天内观察临床症状的变化。同时,在接种病毒后3天内,测定血浆和鼻拭子中病毒量的变化。
临床症状的变化示于表3,血浆中的病毒量示于表4,鼻拭子中的病毒量示于表5。
[表3]
-:无异常,+:跛行,++:不能站立
T-1105非给药组在接种病毒第2天以后,出现跛行、站立困难,足 上形成水泡;与此相比,T-1105给药组的动物均未出现外观上的任何变化。
[表4]
单位:TCID50/μL
T-1105非给药组的血浆中病毒量急剧增加,而T-1105给药组的血浆中病毒量在检出限以下。
T-1105在猪全身感染模型中显示出优良的治疗效果。
[表5]
单位:TCID50/1μL鼻拭子液
T-1105非给药组的鼻拭子中病毒量急剧增加,而T-1105给药组的鼻拭子中的病毒量几乎未增加。
T-1105在猪全身感染模型中显示出优良的治疗效果。
而且,T-1105给药组的猪在给药期间未发现有中毒的现象。
试验例4细胞毒性作用
将含有规定浓度T-1105的培养液以100μL/孔的量添加至96孔板(IWAKI公司制)上。接着,用培养液调配Vero细胞浓度至2×104个/mL, 将所得液体按100μL/孔的量植入,在37℃、5%二氧化碳的条件下培养4天。培养结束时,按照XTT法(例如,癌症研究(CANCER RESEARCH),第48卷,p.4827-4833(1988年)等)测定活细胞数。
T-1105的50%细胞生长抑制浓度(IC50)为250μg/mL以上。
由上述结果可知,T-1105安全性高,且作为猪科动物等用的抗口蹄疫病毒药剂,在由口蹄疫病毒引起的口蹄疫的治疗上有效。
制剂例1 片剂
将10g的T-1105与4.4g乳糖、4.4g结晶纤维素、1.0g羧甲基淀粉钠及0.20g硬脂酸镁混合,并将混合粉末压片,使每片重200mg,得到每片含100mg T-1105的片剂。
制剂例2(复合饲料)
将30g的T-1105与2970g猪用市售饲料(JA全农制)混合,得到1%T-1105复合饲料3000g。在复合饲料中T-1105稳定,24小时不分解。
产业实用性
含有T-1105或其盐的抗口蹄疫病毒药剂在对猪科动物等的口蹄疫的预防或治疗等的处理上有效。
Claims (4)
1.3-氧代-3,4-二氢-2-吡嗪甲酰胺或其盐在制备用于处理猪科动物的口蹄疫的药物中的应用。
2.权利要求1所述的应用,其中,所述处理为预防或治疗。
3.权利要求1或2所述的应用,其中,所述猪科动物为猪。
4.3-氧代-3,4-二氢-2-吡嗪甲酰胺或其盐在制备用于预防或治疗羊的口蹄疫的药物中的应用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP151903/2006 | 2006-05-31 | ||
JP2006151903 | 2006-05-31 | ||
JP2006247698 | 2006-09-13 | ||
JP247698/2006 | 2006-09-13 | ||
PCT/JP2007/060851 WO2007139081A1 (ja) | 2006-05-31 | 2007-05-29 | イノシシ科動物またはヒツジ用抗口蹄疫ウイルス剤およびイノシシ科動物またはヒツジの口蹄疫の予防または治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101454295A CN101454295A (zh) | 2009-06-10 |
CN101454295B true CN101454295B (zh) | 2011-09-21 |
Family
ID=38778601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780019955XA Active CN101454295B (zh) | 2006-05-31 | 2007-05-29 | 猪科动物或羊用抗口蹄疫病毒药剂 |
Country Status (21)
Country | Link |
---|---|
US (1) | US8815842B2 (zh) |
EP (1) | EP2022786B1 (zh) |
JP (1) | JP5161078B2 (zh) |
KR (1) | KR101388061B1 (zh) |
CN (1) | CN101454295B (zh) |
AT (1) | ATE530532T1 (zh) |
AU (1) | AU2007268684B2 (zh) |
BR (1) | BRPI0712561B8 (zh) |
CA (1) | CA2653933C (zh) |
CY (1) | CY1112063T1 (zh) |
DK (1) | DK2022786T3 (zh) |
ES (1) | ES2373469T3 (zh) |
MX (1) | MX2008015181A (zh) |
MY (1) | MY147152A (zh) |
NZ (1) | NZ573108A (zh) |
PL (1) | PL2022786T3 (zh) |
PT (1) | PT2022786E (zh) |
RU (1) | RU2428187C2 (zh) |
SI (1) | SI2022786T1 (zh) |
WO (1) | WO2007139081A1 (zh) |
ZA (1) | ZA200810107B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846617B (zh) * | 2011-07-01 | 2016-01-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-(丁基氧基)-2-吡嗪甲酰氨的制备方法和用途 |
WO2013004092A1 (zh) * | 2011-07-01 | 2013-01-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途 |
CN102617491B (zh) * | 2011-07-01 | 2015-05-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途 |
WO2013004141A1 (zh) * | 2011-07-01 | 2013-01-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-烷氧基取代-2-吡嗪甲酰氨类化合物及其用途 |
KR101690452B1 (ko) | 2016-01-20 | 2016-12-27 | 오형근 | 친환경 효소를 함유한 조성물 제조방법 및 가축용 사료 |
CN107439792A (zh) * | 2017-07-01 | 2017-12-08 | 山东阳春羊奶乳业有限公司 | 一种防治奶山羊口炎的发酵饲料及其制备方法 |
KR102250830B1 (ko) * | 2020-07-17 | 2021-05-11 | 주식회사 농업회사법인 케이푸드 | 유황 돼지 사료 |
KR20220158512A (ko) | 2021-05-24 | 2022-12-01 | 경성대학교 산학협력단 | 마크로락틴 유도체, 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 구제역 바이러스의 감염 질환 예방 또는 치료용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313768A (zh) * | 1998-08-20 | 2001-09-19 | 富山化学工业株式会社 | 含氮杂环羧酰胺衍生物或其盐以及含有二者的抗病毒药 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2927027A (en) * | 1957-11-20 | 1960-03-01 | Du Pont | Feed efficiency promoting composition |
US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
DE3508258A1 (de) | 1985-03-08 | 1986-09-18 | Bayer Ag, 5090 Leverkusen | Ss-lactamantibiotika, verfahren zur herstellung und ihre verwendung als und in arzneimitteln |
JP2000007564A (ja) | 1997-07-16 | 2000-01-11 | Eisai Co Ltd | インドール誘導体を含む抗生剤 |
BRPI0108374B8 (pt) * | 2000-02-16 | 2021-05-25 | Fujifilm Toyama Chemical Co Ltd | derivado de pirazina ou um sal deste e composição farmacêutica |
DE10105306A1 (de) | 2001-02-02 | 2002-08-22 | Nutrinova Gmbh | Futtermittel für die Nutztieraufzucht enthaltend Sorbinsäure und Enzyme |
EP1399132A1 (en) * | 2001-06-08 | 2004-03-24 | Powderject Vaccines, Inc. | Production of hard, dense particles |
-
2007
- 2007-05-29 EP EP07744285A patent/EP2022786B1/en active Active
- 2007-05-29 PT PT07744285T patent/PT2022786E/pt unknown
- 2007-05-29 SI SI200730777T patent/SI2022786T1/sl unknown
- 2007-05-29 AU AU2007268684A patent/AU2007268684B2/en active Active
- 2007-05-29 DK DK07744285.3T patent/DK2022786T3/da active
- 2007-05-29 JP JP2008517933A patent/JP5161078B2/ja active Active
- 2007-05-29 US US12/302,839 patent/US8815842B2/en active Active
- 2007-05-29 RU RU2008152376/15A patent/RU2428187C2/ru active
- 2007-05-29 MY MYPI20084788A patent/MY147152A/en unknown
- 2007-05-29 PL PL07744285T patent/PL2022786T3/pl unknown
- 2007-05-29 WO PCT/JP2007/060851 patent/WO2007139081A1/ja active Application Filing
- 2007-05-29 MX MX2008015181A patent/MX2008015181A/es active IP Right Grant
- 2007-05-29 AT AT07744285T patent/ATE530532T1/de active
- 2007-05-29 CA CA2653933A patent/CA2653933C/en active Active
- 2007-05-29 ES ES07744285T patent/ES2373469T3/es active Active
- 2007-05-29 CN CN200780019955XA patent/CN101454295B/zh active Active
- 2007-05-29 BR BRPI0712561A patent/BRPI0712561B8/pt active IP Right Grant
- 2007-05-29 NZ NZ573108A patent/NZ573108A/en unknown
- 2007-05-29 KR KR1020087031304A patent/KR101388061B1/ko active IP Right Grant
-
2008
- 2008-11-27 ZA ZA2008/10107A patent/ZA200810107B/en unknown
-
2011
- 2011-11-22 CY CY20111101127T patent/CY1112063T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1313768A (zh) * | 1998-08-20 | 2001-09-19 | 富山化学工业株式会社 | 含氮杂环羧酰胺衍生物或其盐以及含有二者的抗病毒药 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0712561B8 (pt) | 2023-12-26 |
EP2022786A1 (en) | 2009-02-11 |
RU2428187C2 (ru) | 2011-09-10 |
AU2007268684A1 (en) | 2007-12-06 |
SI2022786T1 (sl) | 2012-04-30 |
AU2007268684B2 (en) | 2012-02-23 |
BRPI0712561B1 (pt) | 2023-10-24 |
PL2022786T3 (pl) | 2012-06-29 |
CA2653933A1 (en) | 2007-12-06 |
US20090156580A1 (en) | 2009-06-18 |
EP2022786A4 (en) | 2010-07-28 |
EP2022786B1 (en) | 2011-10-26 |
DK2022786T3 (da) | 2012-02-06 |
ZA200810107B (en) | 2010-02-24 |
PT2022786E (pt) | 2012-01-04 |
AU2007268684A8 (en) | 2009-01-08 |
CY1112063T1 (el) | 2015-11-04 |
JP5161078B2 (ja) | 2013-03-13 |
MY147152A (en) | 2012-11-14 |
KR101388061B1 (ko) | 2014-04-22 |
JPWO2007139081A1 (ja) | 2009-10-08 |
US8815842B2 (en) | 2014-08-26 |
ES2373469T3 (es) | 2012-02-03 |
CN101454295A (zh) | 2009-06-10 |
ATE530532T1 (de) | 2011-11-15 |
BRPI0712561A2 (pt) | 2012-11-20 |
NZ573108A (en) | 2011-02-25 |
MX2008015181A (es) | 2008-12-09 |
CA2653933C (en) | 2013-10-08 |
RU2008152376A (ru) | 2010-07-10 |
KR20090027664A (ko) | 2009-03-17 |
WO2007139081A1 (ja) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101454295B (zh) | 猪科动物或羊用抗口蹄疫病毒药剂 | |
EA015481B1 (ru) | Пестицидные композиции | |
CN1816538B (zh) | 病毒感染症的预防或者治疗用组合物 | |
DE60218064T2 (de) | Neues peptid mit angiotensinkonvertase hemmender wirkung | |
Ding et al. | Effects of dietary supplementation with Allium mongolicum Regel extracts on growth performance, serum metabolites, immune responses, antioxidant status, and meat quality of lambs | |
CN102283226A (zh) | 农用防治植物根结线虫的含阿苯哒唑的组合物 | |
CN104839181A (zh) | 一种用于蔬菜的农药组合物 | |
CN1315510C (zh) | 来自洋葱的抗病毒组合物及其治疗用途 | |
JPWO2006082743A1 (ja) | 治療剤 | |
CN103404530A (zh) | 一种杀虫组合物及其应用、制剂 | |
EP1609780A1 (en) | Remedy for diabetes | |
KR20150049696A (ko) | 감태 추출물을 포함하는 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 조성물 | |
KR102106477B1 (ko) | 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용 | |
JP4486273B2 (ja) | いもち病防除剤組成物及び製剤 | |
KR100905772B1 (ko) | 일리시터를 이용한 발아 현미의 제조 방법 및 상기 방법에의해 제조된 발아 현미 | |
WO2019202459A1 (en) | Use of 4-substituted phenylamidine compounds for controlling disease rust diseases in plants | |
KR102534868B1 (ko) | 흰점박이꽃무지 코쿤 추출물을 유효성분으로 함유하는 항균 조성물 | |
JP2000038347A (ja) | 発癌プロモーション抑制剤および飲食品 | |
KR101866286B1 (ko) | 호장근 추출물을 유효성분으로 포함하는 어류의 기생충 감염 질환의 예방 또는 치료용 사료 첨가제 조성물 | |
JP2001302534A (ja) | 肝機能増強剤 | |
CN105557728B (zh) | 农药组合物及其应用 | |
KR101659172B1 (ko) | 신규한 항생활성 화합물 및 그 화합물을 포함하는 항생 조성물 | |
KR20210157589A (ko) | 동애등에 추출물을 포함하는 항균 조성물 | |
KR100493709B1 (ko) | 면역활성 및 항암 효과 증진용 건강 보조식품 | |
JP2002275082A (ja) | 肝機能保護剤または改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |